Pain signals can be interrupted at virtually every step of the pathway between the site of an injury and the brain, and the methods for doing so range from a common over-the-counter pill to experimental gene therapies that silence pain-sensing neurons for weeks. The key insight is that “pain receptors” are not a single switch you flip. They are a chain of molecular events, each of which offers a distinct target for blocking pain. Understanding where along that chain each strategy works helps explain why some approaches suit a short-term injury while others are reserved for intractable chronic pain.
Where Pain Signals Start
The nerve endings that detect potentially harmful stimuli are called nociceptors. They sit in your skin, joints, muscles, and internal organs, and they respond to heat, pressure, chemical irritation, and tissue damage. The largest family of molecular detectors on these nerve endings is the transient receptor potential (TRP) channel group. Six members of that family sit on pain-sensing neurons and convert thermal, chemical, and mechanical stimuli into electrical signals.1PubMed. TRP channels: targets for the relief of pain Think of them as the first domino: a burn, a pinch, or a splash of capsaicin from a hot pepper activates a TRP channel, which lets ions rush into the nerve ending and kicks off an electrical impulse.
That impulse then needs voltage-gated sodium channels to travel along the nerve fiber toward the spinal cord. These channels are what turn a local detection event into a full-blown electrical signal that can reach the brain.2PubMed. The Role of Voltage-Gated Sodium Channels in Pain Signaling Block either the TRP channels at the start or the sodium channels along the way, and the pain message never arrives. Most current and emerging pain treatments target one or both of these steps.
How Common Painkillers Work
The two most widely used classes of pain relief act at completely different points. Non-steroidal anti-inflammatory drugs like ibuprofen and aspirin do not touch the nerve endings directly. Instead, they block the production of prostaglandins, chemical messengers your body releases in response to tissue damage.3PubMed Central. Effects of Nonsteroidal Anti-Inflammatory Drugs at the Molecular Level Prostaglandins do not cause pain on their own, but they lower the threshold at which your nociceptors fire. They make nerve endings more sensitive to stimuli both at the injury site and within the spinal cord.4PubMed. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites By cutting off the prostaglandin supply, NSAIDs bring the pain threshold back to normal. The trade-off is that those same prostaglandins protect the stomach lining, which is why long-term use raises the risk of gastrointestinal side effects.5PubMed Central. Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Gastroprotective NSAIDs on the Gastrointestinal Tract: A Narrative Review
Local anesthetics like lidocaine take the more direct approach of physically blocking sodium channels. They bind inside the channel pore and prevent it from conducting an electrical impulse, which is why an injection at the dentist numbs an entire region.6Frontiers in Pharmacology. The Sodium Channel as a Target for Local Anesthetic Drugs The numbness is not selective: all sensation in that area goes dark, including touch and temperature. That non-selectivity is the main limitation. It works perfectly for a dental procedure or a surgical incision, but it is impractical for chronic pain because you would lose all feeling in the treated area.
A New Generation of Selective Sodium Channel Blockers
The quest for a painkiller that blocks pain without blanking out all sensation has led researchers to focus on specific subtypes of sodium channels. Three subtypes in particular, known as NaV1.7, NaV1.8, and NaV1.9, are heavily concentrated in peripheral pain-sensing neurons rather than in the brain or the rest of the nervous system.7PubMed Central. Targeting Nav Channels for Pain Relief: Structural Insights and Therapeutic Opportunities Blocking one of these selectively could, in theory, silence pain signals while leaving touch, motor control, and cognition untouched.
That theory became clinical reality in January 2025, when the FDA approved suzetrigine (originally called VX-548), the first highly selective NaV1.8 inhibitor for acute pain.8PubMed. Advances in the discovery of selective NaV1.8 inhibitors for pain management In clinical trials, the drug was tested in patients experiencing pain after surgery, and it worked through the peripheral nervous system without acting on the brain the way opioids do.9PubMed. Selective Inhibition of Na(V)1.8 with VX-548 for Acute Pain Suzetrigine is significant because it represents a new mechanism entirely: a non-opioid oral painkiller that targets a pain-specific ion channel. Whether it will prove effective for chronic pain conditions remains an open question, but the fact that this channel can be selectively drugged in humans is a milestone in pain medicine.
The Spinal Gate and How Rubbing a Sore Spot Actually Helps
Not all pain blocking happens out at the nerve endings. One of the most influential ideas in pain science is that the spinal cord acts as a kind of gate. When you rub a bumped elbow, touch-sensing nerve fibers fire alongside the pain fibers, and the touch signals activate inhibitory circuits in the spinal cord that reduce how much of the pain message gets through to the brain.10PubMed Central. Primary Afferent Depolarization and the Gate Control Theory of Pain: A Tutorial Simulation The key mechanism is that touch fibers trigger a kind of chemical brake on the pain fibers right at their first relay point in the spinal cord, weakening the signal before it can travel higher.
More recent work has added nuance to this picture. A population of spinal cord nerve cells has been found to operate what researchers describe as a “leaky gate.” These cells allow mild pain signals through but actively suppress strong pain signals by releasing natural opioid-like molecules called enkephalins.11Neuron. A Subpopulation of Spinal Cord Interneurons Governs a Leaky Gate for Pain and Itch The advantage is that you stay sensitive to gentle warnings while being protected from being overwhelmed by intense pain. When this gate malfunctions, as it can in chronic pain conditions, signals that should be filtered out reach the brain unchecked.
The brain itself also sends signals back down to the spinal cord that can either amplify or suppress pain. This top-down system, called descending modulation, depends heavily on serotonin and norepinephrine. When the descending inhibition weakens, pain is more likely to become chronic, which is one reason drugs that boost norepinephrine activity in the spinal cord, such as certain antidepressants, help some chronic pain patients.12PubMed Central. Descending pain modulation and chronification of pain
Electrical Neuromodulation
If the spinal gate can be closed by touch signals, it follows that delivering controlled electrical pulses near pain-carrying nerves might produce a similar effect. That is the principle behind transcutaneous electrical nerve stimulation (TENS), the small battery-powered units you can buy at a pharmacy and stick to your skin with electrode pads. TENS activates central inhibitory pathways and reduces the excitability of pain-processing neurons in the spinal cord.13PubMed Central. Using TENS for pain control: the state of the evidence Animal and human research has shown that different pulse frequencies engage different brain chemicals: lower frequencies tend to activate opioid-related receptors, while higher frequencies act through a separate set of receptors. In people with fibromyalgia, high-frequency TENS has been shown to restore the body’s ability to dampen incoming pain signals, increasing pain thresholds both at and away from the stimulation site.14Physical Therapy. A Mechanism-Based Approach to Physical Therapist Management of Pain
For more severe chronic pain, implanted devices can deliver stimulation directly to the dorsal root ganglion, a cluster of nerve cell bodies located just outside the spinal cord. In a pooled analysis of over two hundred patients with permanent implants, about two-thirds reported at least a 50 percent reduction in pain at one year, with especially strong results for pain in the foot and groin areas.15PubMed Central. Effectiveness and Safety of Dorsal Root Ganglion Stimulation for the Treatment of Chronic Pain: A Pooled Analysis Mechanistic research in rats has shown that stimulation at the dorsal root ganglion works in part by blocking spontaneous firing in injured nerve fibers, silencing the abnormal signals that drive ongoing neuropathic pain.16PubMed Central. Dorsal root ganglion stimulation of injured sensory neurons in rats rapidly eliminates their spontaneous activity and relieves spontaneous pain
Radiofrequency Ablation
When the goal is longer-lasting pain relief than a nerve block can provide, clinicians sometimes use radiofrequency energy to heat and disable specific nerves. The nerve itself is not removed; instead, the heat damages it enough to interrupt its ability to carry pain signals. This technique is used for knee osteoarthritis, where ablation of the genicular nerves that supply the joint has been shown to provide pain relief that lasts significantly longer than a single nerve block injection, with studies reporting sustained benefit at six and twelve months.17PubMed Central. Comparison of radiofrequency ablation of genicular nerve with genicular nerve block in patients with osteoarthritis of the knee Radiofrequency ablation is also used for abdominal pain from conditions like chronic pancreatitis and cancer, where disabling the splanchnic nerves that relay pain from the abdomen can substantially reduce the need for opioid painkillers.18PubMed Central. Interventional Strategies for Alleviating Severe Abdominal Pain in Chronic Pancreatitis and Abdominal Cancer
The relief is not permanent. Damaged peripheral nerves do regenerate over months, so pain often returns eventually and the procedure may need to be repeated. But for conditions where surgery is not an option and medications are insufficient or poorly tolerated, ablation fills an important gap.
Your Body’s Built-In Pain Blockers
Your nervous system does not just passively receive pain. It actively manufactures its own painkillers. Endorphins and enkephalins are opioid molecules your body produces naturally, and they act on the same receptors that morphine targets. Exercise is one of the most reliable ways to trigger their release. In animal studies, even low-intensity physical activity reversed chronic muscle pain, and this effect was blocked when researchers administered a drug that neutralizes opioid receptors, confirming that the pain relief came from the body’s own opioid system.19PubMed. Low-intensity exercise reverses chronic muscle pain in the rat in a naloxone-dependent manner
The placebo effect also works through these endogenous opioid systems, and it is more biologically real than many people assume. Brain imaging in humans has shown that when people expect pain relief, their brains release endogenous opioids in regions rich with opioid receptors, including the periaqueductal gray, amygdala, and anterior cingulate cortex.20PubMed Central. Placebo effects on human mu-opioid activity during pain More recently, a 2024 study in mice identified a specific brain circuit: neurons in the rostral anterior cingulate cortex projecting to the pontine nucleus, a brain region not previously known to be involved in pain. Activating that pathway produced genuine pain relief even without any placebo conditioning, while inhibiting it blocked placebo analgesia and actually increased pain sensitivity.21Nature. Neural circuit basis of placebo pain relief In other words, the brain has dedicated wiring for expectation-driven pain relief. This does not mean you can just “think away” serious pain, but it helps explain why psychological state and treatment context genuinely change the pain experience at a neurochemical level.
CB2 Cannabinoid Receptors and Pain Outside the Brain
The endocannabinoid system is another built-in pain modulation network, but not all of it lives in the brain. CB1 cannabinoid receptors are widespread in the central nervous system and are responsible for the psychoactive effects of cannabis. CB2 receptors, by contrast, are found primarily outside the brain, on immune cells and peripheral nerves. Drugs that selectively activate CB2 receptors reduce pain without producing the sedation, euphoria, or cognitive impairment associated with CB1 activation.22PubMed Central. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS
In rat models, a selective CB2 agonist reversed both touch sensitivity and heat sensitivity caused by nerve injury, and these effects persisted even in animals completely lacking CB1 receptors, confirming that the pain relief operated entirely through peripheral CB2 pathways.22PubMed Central. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS Even some naturally occurring plant compounds act at CB2 receptors. Beta-caryophyllene, a terpene found in black pepper and cloves, reduced inflammatory and neuropathic pain responses in mice when given orally, and its effects were specifically dependent on CB2 activation.23PubMed. The cannabinoid CB₂ receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain CB2-selective drugs have not yet reached widespread clinical use in humans, but they remain a compelling target because they promise pain relief without central nervous system side effects.
Venom-Derived Painkillers
Some of the most potent natural pain blockers come from animal venoms. Cone snails, slow-moving marine predators, produce a cocktail of tiny proteins called conotoxins that disable specific ion channels with extraordinary precision. One of these, ziconotide, blocks a type of calcium channel found at the terminals of pain-sensing neurons in the spinal cord. By preventing calcium from entering those terminals, it stops the neurons from releasing the chemical signals that would otherwise pass the pain message along. Ziconotide is already an approved drug, delivered directly into the spinal fluid for patients with severe chronic pain who have not responded to other treatments.24PubMed Central. Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain Its existence is a reminder that nature has been engineering ion channel blockers for millions of years, and the pharmaceutical industry is still learning from those designs.
Experimental Frontiers
Further out on the horizon are technologies that could silence pain neurons with remarkable specificity. Optogenetics involves genetically engineering neurons to produce light-sensitive proteins. When those proteins are exposed to a specific color of light, they change the electrical activity of the neuron. In a trigeminal neuralgia model in rats, researchers used a flexible fiber-optic probe to shine yellow light on nerve cells in the trigeminal ganglion, and the light reduced burst firing activity and improved pain-related behaviors including sensitivity to touch and cold.25Frontiers in Cellular Neuroscience. Pain Relief in a Trigeminal Neuralgia Model via Optogenetic Inhibition on Trigeminal Ganglion Itself With Flexible Optic Fiber Cannula Optogenetics requires genetic modification and an implanted light source, so it is a long way from clinical use, but it demonstrates that individual populations of pain neurons can be silenced on demand without affecting neighboring cells.
Gene-based approaches using CRISPR tools are also showing promise. A recent preprint described lipid nanoparticles carrying a modified CRISPR construct that, when injected into the spinal fluid of rodents, dialed down the expression of specific genes in sensory neurons. The targeted genes were involved in recycling the tiny vesicles that neurons use to release chemical signals. By disrupting that recycling process, the treatment reduced signaling from pain neurons while leaving normal acute pain detection and motor function intact. The analgesic effect was long-lasting across models of surgical, inflammatory, neuropathic, and osteoarthritis pain.26bioRxiv. Targeting Synaptic Vesicle Endocytosis in Nociceptors Provides Sustained Pain Relief Because the construct used a reversible gene-silencing approach rather than permanently editing DNA, the effect could theoretically wear off, offering a safety net that permanent gene editing does not.
What People Who Cannot Feel Pain Teach Us
A handful of people worldwide are born with a condition called congenital insensitivity to pain. Many of these individuals carry mutations in the gene SCN9A, which encodes the NaV1.7 sodium channel. Without a functioning NaV1.7 channel, pain signals from the periphery are dramatically weakened or absent. Their existence has been a goldmine for drug developers because they represent a natural experiment in what happens when a specific pain channel is disabled.27PubMed Central. Understanding the genetic basis of congenital insensitivity to pain Several pharmaceutical companies have developed drugs that try to mimic this effect by selectively blocking NaV1.7, though results in clinical trials have been mixed so far. The condition also serves as a cautionary tale: people who feel no pain suffer frequent injuries, burns, and joint damage because pain is a protective signal. Any therapy that silences pain too effectively risks leaving the patient vulnerable.
Neuroinflammation and Glial Cells
One reason chronic pain persists long after an injury has healed is that the immune-like cells of the nervous system, called glial cells, can maintain a state of inflammation in the spinal cord. When microglia become activated, they release inflammatory molecules that keep pain neurons in a heightened state of excitability. This is not the same as the original injury signal; it is the nervous system’s own maintenance crew inadvertently sustaining the alarm. Resolvin D1, a molecule derived from omega-3 fatty acids, has been shown to calm microglial activation and reduce the release of inflammatory signals in both animal tissue and living rodents, leading to measurable pain relief.28PubMed Central. Resolvin D1 accelerates resolution of neuroinflammation by inhibiting microglia activation through the BDNF/TrkB signaling pathway Targeting glial cells rather than neurons is a fundamentally different strategy, and it highlights that chronic pain is often not a problem of the pain receptors themselves but of the environment around them.
This distinction matters practically. If your chronic pain is driven primarily by peripheral nerve damage, a sodium channel blocker or nerve stimulator may help. If it is driven by central neuroinflammation, the same treatments may disappoint. This is part of why chronic pain management remains so difficult: the label “pain” covers multiple biological mechanisms that respond to different interventions, and matching the right tool to the right mechanism is still more art than algorithm.